M&A / Deals UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases pharminent May 4, 2026
Manufacturing Novartis unveils North Carolina API plant as final piece of $23B US expansion pharminent May 1, 2026
Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation pharminent May 1, 2026
Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualified Medicare Beneficiaries (QMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualifying Individuals (QIs) pharminent April 30, 2026
Policy / Pricing Average Drug Fills and Average Gross Drug Costs Per Medicare Part D Enrollee pharminent April 30, 2026
Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy pharminent April 30, 2026
Commercial Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch pharminent April 30, 2026
Commercial Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth pharminent April 30, 2026
Pipeline AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio pharminent April 30, 2026
Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints pharminent April 30, 2026
Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial pharminent April 30, 2026
Commercial Pfizer protects $6.4bn heart disease blockbuster from generics, for now pharminent April 29, 2026
Other FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech pharminent April 29, 2026
Market Access Flash Brief: PBM Reform Collides with MFN Pricing as Midterm Politics Reshape the Drug Pricing Landscape pharminent April 29, 2026
Commercial Pfizer settles with generic drugmakers to protect blockbuster drug until 2031 pharminent April 29, 2026
Regulatory AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions pharminent April 29, 2026
Commercial Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ pharminent April 29, 2026
Manufacturing The strategic investments expanding CDMO capabilities for HPAPIs and ADCs pharminent April 29, 2026
